Sightful Invest
  • Business
  • Investing
  • Politics
  • Stock
Top Posts
Syntholene Selects Papadakis Engineering as Integration Partner for...
Summit Royalties Announces Agreement to Acquire Royalty on Newmont’s...
Lahontan Announces Private Placement
Harvest Gold Expands Its Mosseau Property Along Strike...
CHARBONE presentera a la conference Hydrogen East et...
Tartisan Nickel Corp. Intersects 24.6 Metres of 0.71%...
LaFleur Minerals Inc.Taking Key Steps to Advance Position...
NevGold Mobilizes Drill To Test Historical Leach Pads...
Cartier Cuts 7.1 g/t Au over 8.0 m...
From Biden’s ‘war’ on gas prices to ‘small...
  • Business
  • Investing
  • Politics
  • Stock

Sightful Invest

Politics

Ozempic, Wegovy covered by Medicare and Medicaid under Biden admin proposal for anti-obesity GLP-1 drugs

by admin November 26, 2024
November 26, 2024
Ozempic, Wegovy covered by Medicare and Medicaid under Biden admin proposal for anti-obesity GLP-1 drugs

The Biden administration is expanding coverage of anti-obesity drugs such as Ozempic and Wegovy for people with Medicare and Medicaid through a new proposal from the Department of Health and Human Services, a White House official says. 

Medicare currently only covers these drugs for people who are diagnosed with diabetes or cardiovascular disease with obesity, or for people who are overweight, according to the official, who added that while some state Medicaid programs cover the GLP-1 medications for obesity, many do not. 

The new HHS proposal, they said, would require both Medicare and Medicaid to cover the drugs for people with obesity as a treatment for the condition.

‘Today’s new proposal would expand access to these innovative medications for obesity, which is widely recognized as a disease and help an estimated 3.4 million Americans with Medicare. Medicare coverage would reduce out-of-pocket costs for these prescription drugs by as much as 95 percent for some enrollees,’ the White House said in a statement Tuesday. 

‘Approximately 4 million adult Medicaid enrollees would also gain new access to these medications. This proposal would allow Americans and their doctors to determine the best path forward so they can lead healthier lives, without worrying about their ability to cover these drugs out-of-pocket, and ultimately reduce health care costs to our nation,’ the statement added. 

The White House says that ‘for too many Americans, these critical treatments are too expensive and therefore out of reach,’ and, ‘without insurance coverage, these drugs can cost someone as much as $1,000 a month.’

GLP-1 (glucagon-like peptide) receptor agonists are commonly prescribed to patients with type 2 diabetes (to stabilize blood glucose levels) or obesity (to assist with weight loss). 

‘These medications slow down digestion, which means food stays in the stomach longer,’ said Dr. Alfred Bonati, the founder of the Bonati Spine Institute in Florida, previously told Fox News Digital. 

The White House says an estimated 42 million Americans today have obesity, ‘with increased risk of all-cause mortality and multiple related comorbidities such as diabetes, cardiovascular disease, stroke, some cancers, and more.’ 

‘Over the past few years, there have been major scientific advancements in the treatment of obesity, with the introduction of new life-saving drugs. These anti-obesity medications can help prevent the development of Type 2 diabetes. Furthermore, these drugs reduce deaths and sickness from heart attack and other cardiovascular outcomes by up to 20%,’ the White House added. 

Fox News’ Melissa Rudy contributed to this report. 

This post appeared first on FOX NEWS

previous post
Putin’s ‘Fog of War’ missile confuses experts, but that’s his plan
next post
Stop funding the woke and the stupid

You may also like

Majority of Americans believe Biden will be remembered...

January 8, 2025

Harris’ impact on race with Trump revealed in...

July 23, 2024

Trump assassination attempt: Secret Service makes big change...

August 16, 2024

JOSH HAMMER: Trial lawyer lawfare vs. Trump’s policy...

September 20, 2025

Mike Johnson reveals how he’ll vote on Epstein...

November 18, 2025

Trump courts Japan’s emperor and new PM before...

October 27, 2025

Trump administration takes hard line on Haitian violence,...

May 3, 2025

Since taking office, what are the legal challenges...

February 1, 2025

Exclusive: Hamas document reveals devious paraglider terrorism attack...

August 12, 2024

‘China is our enemy’: GOP lawmaker shoots down...

October 17, 2024

Recent Posts

  • Syntholene Selects Papadakis Engineering as Integration Partner for Novel Thermal-Hybrid Synthetic Fuel Demonstration Facility Heat Exchanger System
  • Summit Royalties Announces Agreement to Acquire Royalty on Newmont’s Saddle North Deposit
  • Lahontan Announces Private Placement
  • Harvest Gold Expands Its Mosseau Property Along Strike To The North And South Adding 24 Claims And 8 Additional Mineral Showings
  • CHARBONE presentera a la conference Hydrogen East et annonce le developpement d’un hub d’approvisionnement dans le marche de l’Atlantique via sa filiale

    Sign up for our newsletter to receive the latest insights, updates, and exclusive content straight to your inbox! Whether it's industry news, expert advice, or inspiring stories, we bring you valuable information that you won't find anywhere else. Stay connected with us!


    By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.

    Categories

    • Business (981)
    • Investing (4,320)
    • Politics (5,200)
    • Stock (4)
    • About us
    • Contact us
    • Privacy Policy
    • Terms & Conditions

    Disclaimer: sightfulinvest.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

    Copyright © 2026 Sightful Invest. All Rights Reserved.